ANTI-CD40 ANTIBODY MUTANTS

摘要

A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.

主权项

1. An antibody prepared by a process comprising:
(i) culturing an animal cell containing (a) a nucleic acid that encodes a heavy chain consisting of an amino acid sequence comprising from Q at position 27 to K at position 474 of SEQ ID NO: 140 and (b) a nucleic acid that encodes an light chain consisting of an amino acid sequence comprising from A at position 23 to C at position 235 of SEQ ID NO: 142 to produce an antibody that binds human CD40; and (ii) purifying the antibody.